for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Kazia Therapeutics Ltd (ADR)

KZIA.OQ

Latest Trade

3.50USD

Change

0.13(+3.70%)

Volume

1,004

Today's Range

3.47

 - 

3.51

52 Week Range

2.14

 - 

4.10

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.38
Open
3.47
Volume
1,004
3M AVG Volume
0.04
Today's High
3.51
Today's Low
3.47
52 Week High
4.10
52 Week Low
2.14
Shares Out (MIL)
62.17
Market Cap (MIL)
21.43
Forward P/E
-2.11
Dividend (Yield %)
--

Latest Developments

More

Kazia Therapeutics Updates On Invesigational New Drug GDC-0084

Kazia Therapeutics Enters Collaboration With Alliance For Clinical Trials In Oncology Foundation

Kazia Therapeutics To Sell Remainder Of Holdings In Noxopharm

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Kazia Therapeutics Ltd (ADR)

Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.

Industry

Biotechnology & Drugs

Contact Info

L 5 20 George St

+61.2.98780088

http://www.novogen.com

Executive Leadership

Iain Ross

Non-Executive Chairman of the Board

James B. Garner

Chief Executive Officer, Executive Director

Bryce Carmine

Non-Executive Deputy Chairman of the Board

Gordon Hirsch

Chief Medical Officer

Lilischkis Kimberley

Clinical & Regulatory Affairs Manager

Key Stats

Revenue (MM, AUD)

2015

0.0K

2017

0.0K

2018(E)

0.0K
EPS (AUD)

2015

-0.120

2017

-2.280

2018(E)

-2.418
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.00
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-47.15
Return on Equity (TTM)
-41.62

Latest News

BRIEF-Kazia Receives FDA Orphan Designation For Gdc-0084

* KAZIA THERAPEUTICS LTD - PHASE II CLINICAL STUDY OF GDC-0084 IS ANTICIPATED TO PROVIDE AN INITIAL DATA READ-OUT IN EARLY CALENDAR 2019 Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Kazia Therapeutics Receives U.S. FDA Orphan Designation For Drug

* RECEIVES U.S. FDA ORPHAN DESIGNATION FOR DRUG FOR TREATMENT OF FORM OF PRIMARY BRAIN CANCER Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up